A5112964488- COVID-19 Clinical Research Studies
- Multiple Sclerosis Research Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Long-Term Effects of COVID-19
- COVID-19 and Mental Health
- Gut microbiota and health
- COVID-19 and healthcare impacts
- Parathyroid Disorders and Treatments
- Barrier Structure and Function Studies
- Venous Thromboembolism Diagnosis and Management
- Acute Kidney Injury Research
- T-cell and B-cell Immunology
- Thyroid and Parathyroid Surgery
- Immune Response and Inflammation
- Politics and Conflicts in Afghanistan, Pakistan, and Middle East
- Immunotherapy and Immune Responses
- Cardiovascular Disease and Adiposity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Schizophrenia research and treatment
- Renal cell carcinoma treatment
- Colorectal Cancer Surgical Treatments
- Airway Management and Intubation Techniques
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Pediatric health and respiratory diseases
Liverpool Heart and Chest Hospital
2022-2025
Royal Brompton Hospital
2025
Liverpool John Moores University
2025
University of Liverpool
2022-2025
St. Thomas Hospital
2025
St Thomas' Hospital
2025
Beaumont Hospital
2025
St. James's Hospital
2024
University of Saskatchewan
2023-2024
Royal College of Surgeons in Ireland
2023
Abstract Post-acute sequelae of COVID-19 (PASC) or the continuation (Coronavirus disease 2019) symptoms past 12 weeks may affect as many 30% people recovering from a SARS-CoV-2 (severe acute respiratory coronavirus 2) infection. The mechanisms regulating development PASC are currently not known; however, hypotheses include virus reservoirs, pre-existing conditions, microblood clots, immune dysregulation, well poor antibody responses. Importantly, neutralizing antibodies essential for...
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Abstract Background Acute kidney injury (AKI) is a recognised complication of coronavirus disease 2019 (COVID-19), yet the reported incidence varies widely and associated risk factors are poorly understood. Methods Data was collected on all adult patients who returned positive COVID-19 swab while hospitalised at large UK teaching hospital between 1st March 2020 3rd June 2020. Patients were stratified into community- hospital-acquired AKI based timing onset. Results Out 448 eligible with...
Cortical tissue injury is common in multiple sclerosis (MS) and associates with disability progression. We have previously shown that HLA-DRB1*15 genotype status the extent of cortical inflammatory pathology. In current study, we sought to examine influence on relationships between inflammation neurodegeneration MS. Human post-mortem MS cases (n = 47) controls 10) were used. Adjacent sections motor cortex stained for microglia (Iba1+, CD68+, TMEM119+), lymphocytes (CD3+, CD8+), GFAP+...
A short-cut review of the literature was carried out to examine potential utility prone positioning in awake patients with hypoxaemic respiratory failure. Four papers were identified as suitable for inclusion using reported search strategy. The author, date and country publication, patient group studied, study type, relevant outcomes, results weaknesses best are tabulated. It is concluded that there no evidence regular failure impacts on clinically outcomes. Further research required...
Aims/Objectives/Background Early experience of the coronavirus pandemic has led to concerns regarding hypercoaguability and increased rates venous thromboembolic (VTE) disease. As a result, many centres have changed front door thromboprophylaxis risk assessment prescribing practice. There is no clear evidence that such new approaches are safe, or improve patient outcomes. We sought establish incidence thrombotic complications in all hospitalised patients with confirmed COVID-19, at UK...
<title>Abstract</title> Post-acute sequelae of COVID-19 (PASC) or the continuation (Coronavirus disease 2019) symptoms past 12 weeks may affect as many 30% people recovering from a SARS-CoV-2 (severe acute respiratory coronavirus 2) infection. The mechanisms regulating development PASC are currently not known; however, hypotheses including poor antibody responses have been suggested. Due to importance virus neutralizing antibodies during recovery and protection reinfection, we designed...